» Articles » PMID: 15480782

Clinical Response to Induction Chemotherapy Predicts Local Control and Long-term Survival in Multimodal Treatment of Patients with Locally Advanced Esophageal Cancer

Overview
Specialty Oncology
Date 2004 Oct 14
PMID 15480782
Citations 20
Authors
Affiliations
Soon will be listed here.
Abstract

Purpose: From 1991 to 1994 we performed a phase II study with intensive preoperative chemoradiation in locally advanced squamous cell carcinoma and adenocarcinoma of the esophagus. We now report on a multivariate analysis of prognostic factors based on the long-term results at a median follow-up of 6.5 years.

Patients And Methods: Eighty-eight patients were treated. Prognostic factors for overall survival and local tumor control were identified by univariate and multivariate analysis.

Results: Median overall survival reached 17 months, and the survival rate at 5 years was 22% (95%-confidence interval: 18-26%). Response to induction chemotherapy was the only independent factor predicting local tumor control and--beside weight loss prior to treatment--it also proved to be an independent prognostic factor for long-term survival.

Conclusions: Intensive chemoradiation followed by surgery seems to be appropriate to improve long-term survival of high-risk patients with locally advanced esophageal cancer. In our trial, local tumor control and prognosis were best correlated with response to induction chemotherapy. These results may help to guide decisions regarding surgery in multimodal treatment of EC. Further efforts are needed to increase the number of treatment responders and to predict tumors not responding to chemo(radio)therapy earlier.

Citing Articles

[What does the general and abdominal surgeon need to know about oncologically oriented radiotherapy?].

Muller J, Trommer S, Meyer F, Lampe K, Croner R, Vordermark D Chirurgie (Heidelb). 2023; 94(5):441-452.

PMID: 36892602 PMC: 10156816. DOI: 10.1007/s00104-023-01820-1.


[Esophageal Cancer].

Bohme F, Racz K, Sebesta Jr C, Sebesta C Wien Med Wochenschr. 2022; 173(9-10):209-215.

PMID: 36318394 DOI: 10.1007/s10354-022-00972-9.


A multinational review: Oesophageal cancer in low to middle-income countries.

Hull R, Mbele M, Makhafola T, Hicks C, Wang S, Reis R Oncol Lett. 2020; 20(4):42.

PMID: 32802164 PMC: 7412736. DOI: 10.3892/ol.2020.11902.


Prognostic significance of combined pretreatment body mass index (BMI) and BMI loss in patients with esophageal cancer.

Gu W, Fang W, Liu C, Pan K, Ding R, Li X Cancer Manag Res. 2019; 11:3029-3041.

PMID: 31114349 PMC: 6489636. DOI: 10.2147/CMAR.S197820.


Variation by stage in the effects of prediagnosis weight loss on mortality in a prospective cohort of esophageal cancer patients.

Shen S, Araujo J, Altorki N, Sonett J, Rodriguez A, Sungur-Stasik K Dis Esophagus. 2017; 30(9):1-7.

PMID: 28859366 PMC: 6036662. DOI: 10.1093/dote/dox073.


References
1.
Walsh T, Noonan N, Hollywood D, Kelly A, Keeling N, Hennessy T . A comparison of multimodal therapy and surgery for esophageal adenocarcinoma. N Engl J Med. 1996; 335(7):462-7. DOI: 10.1056/NEJM199608153350702. View

2.
Alexander E, Lipman T, Harmon J, Wadleigh R . Aggressive multimodality therapy for stage III esophageal cancer: a phase I/II study. Ann Thorac Surg. 2000; 69(2):363-8. DOI: 10.1016/s0003-4975(99)01479-4. View

3.
Bosset J, GIGNOUX M, Triboulet J, Tiret E, Mantion G, Elias D . Chemoradiotherapy followed by surgery compared with surgery alone in squamous-cell cancer of the esophagus. N Engl J Med. 1997; 337(3):161-7. DOI: 10.1056/NEJM199707173370304. View

4.
Ajani J, Komaki R, Putnam J, Walsh G, Nesbitt J, Pisters P . A three-step strategy of induction chemotherapy then chemoradiation followed by surgery in patients with potentially resectable carcinoma of the esophagus or gastroesophageal junction. Cancer. 2001; 92(2):279-86. DOI: 10.1002/1097-0142(20010715)92:2<279::aid-cncr1320>3.0.co;2-2. View

5.
Urschel J, Vasan H . A meta-analysis of randomized controlled trials that compared neoadjuvant chemoradiation and surgery to surgery alone for resectable esophageal cancer. Am J Surg. 2003; 185(6):538-43. DOI: 10.1016/s0002-9610(03)00066-7. View